DDInter1360 DDInter899
Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exists as a racemate in the blood - a pro-drug of the more active (S)-enantiomer is also marketed as a separate anti-epileptic under the name [eslicarbazepine]. Compared to other anti-epileptic drugs, which are generally metabolized via the cytochrome P450 system, oxcarbazepine has a reduced propensity for involvement in drug-drug interactions owing to its primarily reductive metabolism.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Oxcarbazepine {u} (Compound) resembles {v} (Compound) Magnesium salicylate
Oxcarbazepine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxepin
Oxcarbazepine {u} (Compound) resembles {v} (Compound) Clobazam
Oxcarbazepine {u} (Compound) treats {v} (Disease) epilepsy syndrome
Oxcarbazepine {u} (Compound) binds {v} (Gene) SCN5A
Oxcarbazepine {u} (Compound) upregulates {v} (Gene) RRS1
Oxcarbazepine {u} (Compound) palliates {v} (Disease) multiple sclerosis
Oxcarbazepine {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Central Nervous System Disorganized Electrical Activity
Oxcarbazepine {u} (Compound) downregulates {v} (Gene) RBM34
Oxcarbazepine {u} (Compound) causes {v} (Side Effect) Multiple fractures
Oxcarbazepine (Compound) resembles Magnesium salicylate (Compound)
Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Oxcarbazepine (Compound) resembles Clobazam (Compound)
Oxcarbazepine (Compound) treats epilepsy syndrome (Disease)
Oxcarbazepine (Compound) binds SCN5A (Gene)
Oxcarbazepine (Compound) upregulates RRS1 (Gene)
Oxcarbazepine (Compound) palliates multiple sclerosis (Disease)
Oxcarbazepine (Compound) is included by Decreased Central Nervous System Disorganized Electrical Activity (Pharmacologic Class)
Oxcarbazepine (Compound) downregulates RBM34 (Gene)
Oxcarbazepine (Compound) causes Multiple fractures (Side Effect)